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Abstract Expanded polyglutamine (polyQ) stretches lead to
protein aggregation and severe neurodegenerative diseases. A
highly efficient suppressor of polyQ aggregation was identi-
fied, the DNAJB6, when molecular chaperones from the
HSPH, HSPA, and DNAJ families were screened for
huntingtin exon 1 aggregation in cells (Hageman et al. in
Mol Cell 37(3):355–369, 2010). Furthermore, also aggrega-
tion of polyQ peptides expressed in cells was recently found to
be efficiently suppressed by co-expression of DNAJB6 (Gillis
et al. in J Biol Chem 288:17225–17237, 2013). These sup-
pression effects can be due to an indirect effect of DNAJB6 on
other cellular components or to a direct interaction between
DNAJB6 and polyQ peptides that may depend on other cel-
lular components. Here, we have purified the DNAJB6 protein
to investigate the suppression mechanism. The purified
DNAJB6 protein formed large heterogeneous oligomers, in
contrast to themore canonical familymemberDNAJB1which
is dimeric. Purified DNAJB6 protein, at substoichiometric
molar ratios, efficiently suppressed fibrillation of polyQ pep-
tides with 45°Q in a thioflavin T fibrillation. No suppression
was obtained with DNAJB1, but with the closest homologue
to DNAJB6, DNAJB8. The suppression effect was indepen-
dent of HSPA1 and ATP. These data, based on purified pro-
teins and controlled fibrillation in vitro, strongly suggest that
the fibrillation suppression is due to a direct protein–protein
interaction between the polyQ peptides and DNAJB6 and that
the DNAJB6 has unique fibrillation suppression properties
lacking in DNAJB1. Together, the data obtained in cells and
in vitro support the view that DNAJB6 is a peptide-binding
chaperone that can interact with polyQ peptides that are in-
completely degraded by and released from the proteasome.
Keywords Aggregation . Amyloid . DNAJ . Molecular
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Introduction
Among the various molecular chaperone families, the DNAJ
family is the largest and most heterogeneous group, named
after their common nominator, the J domain, which is re-
sponsible for the interactions with the ATP-dependent Hsp70
(HSPA) refolding machinery. Canonically, the DNAJ pro-
teins bind to substrate proteins, transport, and present them
to Hsp70 for refolding. The J domain also stimulates the
ATPase activity of Hsp70. The DNAJ family members are
thought to be responsible for substrate specificity (Kampinga
and Craig 2010). Molecular chaperones in the protein quality
control system assist folding and degradation of substrate
proteins (Tyedmers et al. 2010) and suppress aggregation
and cytotoxicity induced by heat shock or other proteotoxic
insults (Kampinga 1993; Morimoto 2008).
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Neurodegenerative polyglutamine diseases are caused by
a CAG triplet expansion in the affected gene, which leads to
an aggregation-prone prolonged polyglutamine (polyQ)
stretch in the encoded protein (Gatchel and Zoghbi 2005).
Stretches with polyQ occur in many human proteins, e.g., in
transcription factors. This suggests that such polyQ stretches
have an evolutionary early and important cellular function
(Ramazzotti et al. 2012; Schaefer et al. 2012). The normal
form of the human huntingtin (Htt) protein contains a polyQ
stretch of 11 to 34 glutamines in exon 1 (HttEx1). An
expansion of the number of glutamines to above 35 leads
to Huntington’s disease (HD), a severe disease hallmarked
by protein fibrillation and neuronal inclusion body forma-
tion, linked to a progressive neurodegenerative process with
uncontrolled movements, personality changes, and cognitive
impairment. The length of the polyQ stretch is statistically
related to the age of onset of HD: the longer, the earlier the
onset of symptoms (Novak and Tabrizi 2010). Fibrillation
propensity is also dependent on polyQ length as shown in
several cell and animal models as well as in vitro data with
purified proteins (de Almeida et al. 2002; Kar et al. 2011).
All these suggest that aggregation initiates disease, although
the nature of the toxic entities (fibrils or precursor oligomeric
forms) that cause neurodegeneration is subject to debate.
Various molecular chaperones have been studied for their
involvement in polyQ diseases (Gestwicki and Garza 2012).
Within the DNAJ protein family, the HSJ1a (DNAJB2a)
(Labbadia et al. 2012) and DNAJB1 (Lotz et al. 2010) have
been reported to suppress polyQ aggregation in cooperation
with the Hsp70 machinery. However, in a cell-based screen
of various molecular chaperones from the HSPH, HSPA, and
DNAJ families, the most effective to suppress polyQ aggre-
gation are two closely related DNAJ homologues, DNAJB6
and DNAJB8 (Hageman et al. 2010). Suppression had pre-
viously been observed for DNAJB6 in a human cell line
(Chuang et al. 2002) and for the Drosophila ortholog Mrj-
1 (Fayazi et al. 2006). Interestingly, the suppression of polyQ
aggregation by DNAJB6 (Hageman et al. 2010) was found to
be independent of the Hsp70 machinery. In fact, the N-
terminal J domain, required for Hsp70 interactions, was
largely dispensable for this effect.
The mechanism of polyQ fibrillation and the influence of
the polyQ context within proteins are not fully understood at
the molecular level (Bieschke et al. 2012; Wetzel 2012).
Aggregation in nine different polyQ diseases (HD, x-linked
spinal and bulbar muscular atrophy, dentatorubral-
pallidoluysian atrophy and six forms of spinocerebellar ataxia)
is tightly associated with polyQ stretches in nine functionally
and structurally unrelated proteins (Zoghbi and Orr 2000).
Furthermore, polyQ stretches fused to green fluorescent pro-
tein (GFP) affect, for example, motility in Caenohabditis
elegans models (Morley et al. 2002), and polyQ stretches
alone cause toxicity in Drosophila (Marsh et al. 2000).
Thus, it appears that it is the polyQ stretches that drive
aggregation.
Several reports suggest that aggregation initiation is asso-
ciated with processing of polyQ-containing proteins by pro-
teases, since the full-length polyQ-containing proteins are
less prone to aggregation (Harris et al. 2010; Ratovitski et al.
2009). The context around the polyQ stretch does seem,
however, important, probably, both for its processing into
such smaller fragments (Wellington et al. 1998; Berke et al.
2004; Jung et al. 2009; Graham et al. 2006) as well as for the
(co)aggregation proneness of the generated fragments
(Dehay and Bertolotti 2006). The proteasome is unable to
cleave expanded polyQ stretches (Holmberg et al. 2004;
Venkatraman et al. 2004). Proteasomal processing of
polyQ-containing proteins or fragments generated thereof
may therefore yield highly aggregation-prone polyQ pep-
tides (Raspe et al. 2009), not readily digested by peptidases
(Menzies et al. 2010). These polyQ peptides could thus be a
major initiator of aggregation and disease, by seeding the
aggregation of polyQ-containing proteins. Recently, cellular
polyQ aggregation, initiated by overexpression of peptides
with expanded polyQ stretches, was found to be efficiently
suppressed by co-expression of DNAJB6 and DNAJB8
(Gillis et al. 2013). Such suppression could be due to either
an indirect effect on other cellular components or to a direct
interaction between DNAJB6/DNAJB8 and polyQ peptides.
In order to obtain further evidence for a direct interaction
between DNAJB6 and polyQ and to gain insight into the
suppression mechanism, we decided to purify the proteins,
focusing on the functional characterization of DNAJB6 since
it is ubiquitously expressed, including in the brain, whereas
DNAJB8 is only expressed in the testis (Hageman et al.
2010). We decided to evaluate the suppression by thioflavin
T binding, which is among the most widely used tools in the
study of amyloid fibrils (Biancalana and Koide 2010; Wu
et al. 2010), using purified polyQ peptides as well as purified
polyQ constructs within a HttEx1 context. We found that the
purified DNAJB6 protein formed large heterogeneous olig-
omers, consistent with the oligomeric state found in human
cell lines, and that DNAJB6 efficiently suppressed the fibril-
lation of polyQ peptides under conditions where DNAJB1
and the Hsp70 machinery had no effect.
Materials and methods
Recombinant expression and purification of DNAJB6/8
The human DNAJB6b and DNAJB8, cloned and sequenced
as previously described (Hageman et al. 2010), were
subcloned into pET/TOPO-151 vector (Invitrogen, Paisley,
UK) containing a hexa His-tag, a V5-tag, and a tobacco etch
virus (TEV) protease cleavage site. The plasmids were
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transformed into Escherichia coli strain ER2566 and grown
in LBmedium with 50 mg/l ampicillin. Overnight cultures of
5 ml were used to inoculate 500 ml cultures in 2.5-l baffled
flasks in a shaker at 37 °C. Isopropyl β-D-1-thiogalactopy-
ranoside was added at OD600=1, and cells were collected 3–
4 h later by centrifugation at 6,000×g for 5 min and frozen at
−20 °C. Cell pellets were dissolved in buffer (20 mM sodium
phosphate buffer, pH 8.0, 150 mM NaCl, 5 mM dithiothreitol
(DTT)), with DNAse (Sigma-Aldrich, Stockholm, Sweden)
and protease inhibitor (cOmplete EDTA free; Roche
Diagnostics Scandinavia AB, Stockholm, Sweden) added just
prior to cell lysis, which was performed by passing twice
through a French press, followed by centrifugation at
20,000×g. The supernatant was discarded, the pellet was
washed in the same buffer including 0.75 % Tween-20, cen-
trifugation was repeated, and pellet was finally resuspended in
the same buffer without Tween-20, but with 8 M urea, which
was, thereafter, aliquoted and stored at −20 °C. For affinity
chromatography, the sample was thawed and diluted tenfold
in the same buffer with no urea, and imidazole was added to a
final concentration of 20 mM. The sample was loaded on the
HisTrap column (GE Healthcare Lifesciences, Uppsala,
Sweden), washed with buffer containing 20 mM imidazole,
and eluted with buffer containing 350 mM imidazole. The
His-tag was cleaved with TEV protease (Invitrogen, Paisley,
UK) at a protein concentration of 1 mg/ml and 1 unit protease
per 3 μg protein at 20 °C overnight. After cleavage, the
sample was diluted with imidazole-free buffer and concen-
trated using the Centriprep centrifugal filter devices
(Millipore AB Sweden, Solna, Sweden) and applied a
second time to the HisTrap column. The flow-through
was collected and contained the His-tag-free proteins,
whereas the cleaved off His-tag, any remaining uncleaved
His-tagged protein, and the TEV protease, which contains
a non-cleavable His-tag, were retained on the column.
Protein concentration was determined using the Bradford
assay (Bradford 1976; Stoscheck 1990) with bovine serum
albumin (BSA) as standard. Non-denaturing (native poly-
acrylamide gel electrophoresis (PAGE)) and sodium
dodecyl sulfate (SDS)-PAGE was performed using precast
3–12 % NativePAGE Bis-Tris Gels and precast 4–12 %
NuPAGE® SDS-PAGE Bis-Tris Gels (Life Technologies
Europe BV, Stockholm, Sweden), stained with colloidal
Coomassie Brilliant Blue (Lawrence and Besir 2009) and
scanned with the Image Scanner III using the software
Labscan/IQTL (GE Healthcare Lifesciences, Uppsala,
Sweden).
Dynamic light scattering
Dynamic light scattering (DLS) measurement was used to
assess particle size using the Zetasizer Nano S (Malvern
Instruments, Malvern, UK) amenable for measurements on
particles between 0.3 nm to 10 μm.
Size exclusion chromatography
Size exclusion chromatography (SEC) was performed by gel
filtration using the HiPrep Sephacryl S-400 16/60 column (GE
Healthcare Lifesciences, Uppsala, Sweden). The column was
equilibrated with buffer (20 mM sodium phosphate buffer, pH
8.0, 150 mM NaCl) and operated at a flow rate of 0.5 ml/min
at 4 °C. Fractions of 0.5 ml were collected and protein elution
followed by detection of the absorbance at 280 nm.
Expression and purification of maltose-binding
protein-fused HttEx1 and polyQ peptide
Recombinant C-terminally hexa His-tagged maltose-binding
protein (MBP)-TEV-HttEx1Qn and N-terminally hexa His-
tagged MBP-TEV-Qn of varying lengths (n=15 and 45) were
expressed in E. coli strain BL21(DE3) (Stratagene, Santa
Clara, CA, USA) and purified in three steps. The proteins
were first eluted from the 10-ml bed volume Talon metal
affinity resin column (Clontech, Saint-Germain-en-Laye,
France), equilibrated in 20 mM Tris–HCl, pH 7.5; 100 mM
KCl; 20 mM imidazole; 10 % glycerol; and 1 mM DTT by
developing an imidazole gradient (20–500 mM). The His-
tagged MBP-TEV-HttEx1Qn and the MBP-TEV-Qn of vary-
ing lengths were eluted from this column in 200 mM imidaz-
ole. The fractions containing His-tagged MBP-TEV-
HttEx1Qn were pooled and loaded on the UnoQ6 column
(BioRad, Marnes-la-Coquette, France) equilibrated in
20 mM Tris–HCl, pH 7.5; 20 mM KCl; and 1 mM DTT.
The column was washed with five bed volumes of the equil-
ibration buffer, and the fusion proteins were eluted using a
KCl gradient (20–500 mM). His-tagged MBP-TEV-
HttEx1Qn eluted from this column at 200 mM KCl, and their
concentrations were determined from their absorbance at
280 nm using an extinction coefficient of 67840 M−1 cm−1.
Removal of MBP from HttEx1
MBP-TEV protease, produced using the plasmid pRK1043
(Addgene, Cambridge, MA, USA), was added to the eluted
protein at a 1:5w/w ratio and 100 % cleavage, as assessed
using SDS-PAGE, and was achieved upon incubating the
mixture for 1 h at 37 °C. The mixture was then loaded on the
1-ml bed volume Talon column, the column was washed
with 20 bed volumes of 20 mM Tris–HCl, pH 7.5, and
100 mM KCl, and HttEx1Qn was eluted in 20 mM Tris–
HCl, pH 7.5; 100 mM KCl; and 200 mM imidazole. The
protein was immediately desalted using PD-10 desalting
columns (GE Healthcare, Uppsala, Sweden) equilibrated in
50 mM HEPES–KOH, pH 7.5, and 150 mM NaCl;
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aliquoted; flash frozen in liquid nitrogen; and stored at
−80 °C until use. The protein concentrations in the final
eluate were systematically comparable to that following
cleavage as assessed by SDS-PAGE analysis.
Removal of MBP from polyQ peptide
The fractions containing hexa His-tagged MBP-TEV-Qn
(1.5 mg/ml) were incubated with His-tagged TEV (0.3 mg/
ml) (Invitrogen, Paisley, UK) for 20 min at room tempera-
ture. The mixture was then diluted tenfold and loaded on the
5-ml bed volume HiTrap Q FF column (GE Healthcare,
Uppsala, Sweden). The column was washed with ten bed
volumes of 20 mM HEPES, pH 7.5, and Qn peptides was
eluted in 20 mM HEPES, pH 7.5, and 300 mM NaCl. His-
tagged MBP and TEV were trapped in-line on the 10-ml
Talon column. The Qn peptides were immediately aliquoted,
flash frozen in liquid nitrogen, and stored at −80 °C until use.
Electron microscopy
The DNAJB6 protein was applied to glow discharged carbon-
coatedgridsandstainedwith1%uranylacetate fornegativestain
electronmicroscopy (EM). Imageswere recorded, using a JEOL
JEM2100Fmicroscope at 200 kVand amagnification of 40,000
times, equippedwith theTietz 4k×4kCCDcamera (TietzVideo
and Image Processing Systems GmbH, Gauting, Germany).
HttEx1Qn and Qn assemblies were observed by TEM in the
JEOL1400 transmission electronmicroscope following adsorp-
tion onto carbon-coated 200-mesh grids and negative staining
with 1 % uranyl acetate. The images were recorded with the
Gatan Orius CCD camera (Gatan,München, Germany).
Fibrillation assay based on thioflavin T fluorescence increase
The constructs of purified His-tagged MBP-TEV-HttEx1Qn
and MBP-TEV-Qn of varying lengths were used to monitor
fibril formation by continuous measurement of thioflavin T
(ThT) fluorescence increase (Linse et al. 2007). The final
volume was 100 μl per well in a 96-well, low-binding, half-
area microplate (Corning 3881; Corning Incorporated Life
Sciences, Acton, MA) kept on ice, while constructs from
30 μM stock solutions were mixed to a final concentration of
15 μM (or as else stated) with filtered and degassed buffer
(Tris–HCl, pH 7.4 and 150 mMKCl); the final concentration
of ThTwas 10 μM, and the final concentration of DNAJB6,
DNAJB8, and DNAJB1 (obtained from Sigma-Aldrich,
Stockholm, Sweden) was varied as stated in figure legends.
All molar ratios between proteins are calculated on a
monomer-to-monomer basis, although the same oligomeric
DNAJB6 protein was used in all assays. HSPA1 (Sigma-
Aldrich, Stockholm, Sweden) was added in a molar ration to
DNAJB of 2:1, together with 2 mM ATP and 5 mM MgCl2.
After adding TEV protease (molar ratio protein to protease
50:1), the microplate plate was sealed with a plastic film to
avoid evaporation and immediately inserted into the plate
reader FLUOstar Omega (BMG Labtech, Offenburg,
Germany) and incubated at 37 °C without agitation. ThT
fluorescence was recorded every 150 s through the bottom
of the plate with excitation and emission filters of 440 and
480 nm, respectively. Fibrillation under seeded conditions was
performed by adding preformed fibrils, from a fibrillation
assay experiment on the previous day, corresponding to an
additional 5 or 20 % of the monomer concentration (10 μM).
Fibrillar assembly monitored as formation of SDS-insoluble
material
The assembly of purified HttEx1Qn and Qn peptides into
fibrils was monitored also by SDS-PAGE as disappearance
of the band corresponding to monomeric, SDS-soluble
HttEx1Q45 and Q45 and concomitant appearance of SDS-
insoluble material accumulated at the top of the gel using 13%
Tris–tricine (Q45) or 12 % Tris–glycine (HttEx1Q45) gels
stained with SYPRO Orange (Invitrogen, Paisley, UK)
followed by imaging with a LAS-3000 (Fujifilm, Tokyo,
Japan) using the software Multigauge (Life Science
Systems), for quantification of protein bands. Experiments
were performed two to six times, and the data presented are
representative of the experiments we performed.
Secondary structure prediction of DNAJB6 and sequence
alignment
The sequences of human DNAJB6 (isoform B, sp|O75190-
2) and DNAJB8 (sp|Q8NHS0), three ortogues to each of
them, and human DNAJB1 (sp|P25685) were subjected to
secondary structure prediction using several different pro-
grams (JPRED, APSSP, NetSurfP, PROF, SCRATCH,
JUFO, PSIPRED, YASPIN, PORTER, and PROTPRED) at
ExPASy website (http://www.expasy.org) and compared to
the secondary structure determined for human DNAJB1, the
N-terminal domain (PDB 1HDJ; Qian et al. 1996), and the
C-terminal domain (PDB 3AGX; Suzuki et al. 2010).
Sequence alignment was performed with Clustal Omega
(www.ebi.ac.uk/Tools/msa/clustalo).
Results
DNAJB6 is an oligomeric protein
The DNAJB6 was recombinantly expressed in E. coli and
purified by affinity chromatography (Fig. S1, Table S1). The
His-tag was removed by cleavage with TEV protease, and
when occasionally, the cleavage was incomplete; not only
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His-tagged DNAJB6 but also untagged DNAJB6 was
retained on the column. This suggested that the purified
DNAJB6 protein is not in a monomeric form, in consistence
with the findings that in cells, DNAJB6 (Sarparanta et al.
2011) as DNAJB8 (Hageman et al. 2010) forms large oligo-
mers. The oligomeric state of DNAJB6 was further analyzed
by DLS (Fig. 1a), SEC (Fig. 1b), native PAGE (Fig. 1c), and
negative stain EM (Fig. 1d), altogether revealing a polydis-
perse population of particles, with an average radius size of
12.7 nm (Table 1). The size distribution of the oligomers was
similar for DLS measurements at temperatures from 10 to
40 °C and at concentrations ranging from 0.03 to 3 mg/ml
(data not shown). Attempts to fractionate the heterogeneous
DNAJB6 oligomers by SEC resulted in subpopulations of
different size, as seen with native PAGE (Fig. 1c) and DLS
(Table 1), which, however, still were heterogeneous. So, un-
like what is known for most other DNAJB proteins that,
generally, are thought to form dimers (Kampinga and Craig
2010; Cheetham and Caplan 1998; Li et al. 2009), DNAJB6
forms large and polydisperse oligomers.
Assessment of PolyQ fibrillation
The high propensity of polyQ to form β-sheet-rich fibrils is
documented by different experimental techniques, including
CD, EM, and X-ray diffraction (Papaleo and Invernizzi 2011).
That fibrils bind the fluorescent dye ThT (Krebs et al. 2005) is
underlying one of the most widely used tools in the study of
amyloid fibrils (Biancalana and Koide 2010; Wu et al. 2010).
We evaluated the effect of DNAJB6 on fibrillation, with
polyQ as a peptide (Qn) and in the context of HttEx1
(HttEx1Qn), with Q =15 or 45. The sequences were
GAMKSF (Q )nF and GAMATLEKLMKAFESL
KSF(Q)nPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPP
PPPPPGPAVAEEPLHRPGSLHHHHHH (with residues in
HttEx1 underlined), resulting in molecular mass 6.5 and
Fig. 1 DNAJB6 forms large
heterogeneous oligomers.
Purified DNAJB6 protein was
analyzed by DLS (a) and SEC
(b), with molecular weight
marker in gray dashed line.
Fractions of the oligomeric
DNAJB6 peak, of which three
are marked 3, 6, and 9, were
further analyzed with native
PAGE (c) where MW molecular
standard, lane 1 unfractionated
sample, and lanes 2–10 SEC
fractions. The fractions marked
with an asterisk were also
analyzed with DLS (Table 1),
and fraction 6 was stained with
uranyl acetate for negative stain
EM (d) with a scale bar
corresponding to 100 nm
Table 1 Size determination of DNAJB6 oligomers by DLS
SEC fraction Radius size SD MW SD
(nm) (kDa)
Unfractionated 12.7 4.7 1,280 478
3 13.2 3.3 1,400 352
6 10.8 2.8 880 231
9 10.4 2.5 810 196
Values are presented from DLS measurements of DNAJB6 oligomers,
without (unfractionated) and with (fractionated: 3, 6, and 9) prior
fractionation by SEC (Fig. 1b). Same fractions were also analyzed by
native PAGE (Fig. 1c)
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14 kDa, respectively, for n=45. Since the constructs are
highly prone to aggregation, they were expressed and purified
as fusions with MBP (Fig. S2). Fibrillation was initiated by
addition of TEV protease, which starts the release of the
fibrillation-prone polyQ monomers fromMBP, and was mon-
itored by continuous measurement of ThT fluorescence. For
both Q45 (Fig. 2a) and HttEx1Q45 (Fig. 2b), fibrillation
occurred in a concentration-dependent manner, as previously
reported (Wetzel 2012). To yield information on the dominat-
ing fibrillation pathway (Cohen et al. 2012), half times of
fibrillation were extracted (Table 2) from the curves in
Fig. 2a, b. A power function was fitted to t0.5 versus concen-
tration c (t0.5=C×c
k), whereC is a constant, and k is the slope
in the log–log plot (Fig. 2c). Assuming a dimer as critical
nucleus, these k values for Q45 and HttEx1Q45 (−1.2 and
−1.3, respectively) suggest that the fibrillation was largely
dependent on the so-called primary nucleation (Cohen et al.
2012). No increase in ThT fluorescence was observed neither
for Q15 nor HttEx1Q15 (data not shown). In agreement with
this, no fibrils were observed by for Q15 nor HttEx1Q15
(Fig. 2d, f), whereas the increase in ThT fluorescence intensity
recorded both for Q45 and HttEx1Q45 correlated with the
appearance of fibrils (Fig. 2e, g).
Suppression of polyQ fibrillation by DNAJB6 Having
established a robust fibrillation assay for Q45 and HttEx1Q45,
Fig. 2 Concentration-dependent
polyQ fibrillation. Fibrillation
was measured as the ThT
fluorescence increase, and
triplicate samples are shown for
Q45 peptide (a) and for
HttEx1Q45 (b), at protein
concentrations 6.4, 8, 10, 12.8,
16, and 20 μM, color coded with
increasingly darker blue
indicating increasing
concentration. The difference in
absolute fluorescence intensity
between Q45 and HttEx1Q45 is
arbitrary and gives no
quantitative comparison of their
extent of fibrillation. Half times
of fibrillation (t0.5 values,
Table 2) were extracted from the
curves in a and b and log t0.5
plotted against the log
concentration of Q45 peptide and
HttEx1Q45, respectively (c).
Samples of polyQ peptide (d, e)
and HttEx1 (f, g) with Q15 (d, f)
or Q45 (e, g) were visualized
with TEM to confirm fibril
formation. Scale bars
correspond to 200 nm
Table 2 Concentration-dependent PolyQ fibrillation
Concentration Q45 HttEx1Q45
(μM) t0.5 (h) SD t0.5 (h) SD
6.4 16.0 0.2 8.9 0.3
8 11.6 0.2 6.3 0.0
10 9.2 0.1 4.4 0.1
12.8 7.2 0.3 3.3 0.1
16 5.3 0.0 2.6 0.1
20 4.1 0.1 2.2 0.0
Fibrillation was measured as ThT fluorescence increase at various
concentrations of polyQ. The half time (t0.5) for fibrillation was
extracted from the curves in Fig. 2a (Q45) and Fig. 2b (HttEx1Q45),
respectively, and plotted in Fig. 2c
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we next assessed the effect of DNAJB6 on fibrillation. The lag
phase preceding fibrillation increased with increasing concen-
trations of DNAJB6 (Fig. 3). For Q45 (Fig. 3a), fibrillation
suppression occurred at a molar ratio polyQ to DNAJB6 as
low as 1:0.01. For HttEx1Q45, the fibrillation suppression was
less efficient (Fig. 3b). Suppression can be estimated as the
increase in the t0.5 values for fibrillation and was increased by
DNAJB6 approximately tenfold for Q45 at a 1:0.1 M ratio, but
only by a factor of 3 for HttExQ45 at a similar molar ratio. At
lower molar ratio (1:0.01), the t0.5 of fibrillation was increased
by a factor of 2 for Q45, while no significant effects were seen
for HttEx1Q45.
Suppression of polyQ fibrillation by DNAJB6 in presence of
preformed fibrils To investigate the mechanism of fibrilla-
tion suppression further, we performed experiments under
seeded conditions to mimic later stages where some nuclei
have been formed already, and elongation of fibrils and
secondary nucleation processes may occur (Cohen et al.
2012). Fibrillation suppression by added DNAJB6 was eval-
uated without seeding (primary nucleation dominates) and
by seeding with preformed fibrils at two concentrations (5 %,
secondary nucleation may dominate, and 20 %, the elonga-
tion of fibrils dominates), for Q45 (Fig. 4a) and HttEx1Q45
(Fig. 4b). The suppression was largest under non-seeded
Fig. 3 Suppression of fibrillation of Q45 and HttEx1Q45 by DNAJB6.
Fibrillation was measured in triplicates as the relative ThT fluorescence
increase, at 15 μM Q45 (a) or HttEx1Q45 (b) with DNAJB6 added in
varying polyQ to DNAJB6 molar ratios: 1:0.1 (red), 1:0.01 (dark pink),
1:0.001 (pink), no added DNAJB6 (black), and BSA added in ratio
1:0.1 (yellow green). Note the difference in time scale between Q45 and
HttEx1Q45. Molar ratios were calculated as monomer to monomer,
although DNAJB6 is oligomeric
Fig. 4 Suppression of fibrillation of Q45 and HttEx1Q45 by DNAJB6 in
the presence of preformed fibrils. Fibrillationwasmeasured as the relative
ThT fluorescence increase at 10 μM Q45 (a) or HttEx1Q45 (b) under
different seeding conditions: no seed (black) without and with DNAJB6
(red), seeding with 5 % preformed fibrils (dark blue) without and with
DNAJB6 (purple), seeding with 20 % preformed fibrils (light blue)
without and with DNAJB6 (pink), with preformed fibrils taken after
20 h of incubation according to Fig. 3. The molar ratio between chaperone
and polyQ was 1:0.01 for Q45 and 1:0.1 for HttEx1. Molar ratios were
calculated as monomer to monomer, although DNAJB6 is oligomeric
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conditions, but not insignificant under seeded conditions.
Thus, there is clearly an effect of DNAJB6 not only on the
primary nucleation but also on later stages of fibrillation.
Suppression of the formation of SDS-insoluble aggregates by
DNAJB6 As a complement to the evaluation of polyQ aggre-
gation as the formation of fibrils by ThT fluorescence mea-
surements, we also followed the polyQ aggregation by contin-
uous withdrawal of samples for SDS-PAGE and assessment of
the distribution of protein between bands representing the
monomeric forms of Q45 and HttEx1Q45, respectively
(Fig. 5a, c) and bands representing SDS-insoluble aggregates
at the top of the gel (Fig. 5b, d). Quantification of the band
intensities after imaging showed disappearance of monomeric
forms (Fig. 5e, f) and concomitant appearance of SDS-
insoluble aggregates (Fig. 5g, h), in approximately 24 h for
Q45 and 1 h for HttEx1Q45. Thus, for Q45, the formation of
ThT-binding fibrils (Fig. 3a) preceded the formation of SDS-
insoluble aggregates (Fig. 5c), whereas for HttEx1Q45, the
formation of ThT-binding fibrils (Fig. 3b) and aggregates




polyQ aggregates was followed
on SDS-PAGE for 20 μM Q45
(a, c) and Ex1Q45 (b, d) in the
absence (a, b) or presence (c, d)
of 20 μM DNAJB6. Gels were
stained for 1 h (b, d) or 3 h (a, c)
with SYPRO Orange. This dye is
poorly bound to HttEx1Q45 and
even more so to Q45, which
appear as faintly stained bands
on the gels, despite being present
at much higher levels than
DNAJB6. Protein band
intensities were quantified and
plotted as a relative amount of
soluble monomers (e, f) or SDS-
insoluble aggregates (g, h) at
20 μM Q45 (e, g) and
HttEx1Q45 (f, h) without
DNAJB6 (filled circles) or with
DNAJB6 in a molar ratio of 1:0.1
(open diamonds) or 1:1 (filled
squares). Molar ratios were
calculated as monomer to
monomer, although DNAJB6 is
oligomeric. Note the difference
in time scale between Q45 and
HttEx1Q45. The data were fitted
to the sigmoidal equation y=a/
(1+exp(b(c−x))), where a is the
proportion of aggregates at
steady state, b is the slope of the
exponential growth phase, and c
is the time where 50 % of the
aggregation is reached
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(Fig. 5d) occurred rather simultaneously and more rapidly than
for Q45. This is consistent with previous observations of
peptides relative to the exon 1 of huntingtin, where the N-
terminal 17 amino acids cause an initial aggregation prior to
rearrangement and fibril formation (Papaleo and Invernizzi
2011). Equimolar amounts of DNAJB6 fully prevented aggre-
gation of Q45 during 84 h (Fig. 5a, c), and delayed it fourfold
forHttEx1Q45 (Fig. 5b, d).With substoichiometric amounts of
DNAJB6 (1:0.1), the monomeric form of Q45 and HttEx1Q45
disappeared, and the same amount of SDS-insoluble aggre-
gates appeared in case of HttEx1Q45, but not for Q45 (Fig. 5d,
compared to c). Hence, even substoichiometric amounts of
DNAJB6 interact with Q45 monomers and counteract the
appearance of insoluble aggregates.
Fig. 6 Specificity in suppression of fibrillation by DNAJB6. Fibril-
lation was measured as the relative ThT fluorescence increase, and
incubation was made at 15 μM Q45 (a) and HttEx1Q45 (b) with no
chaperone (black), DNAJB6 (red), DNAJB8 (green), and DNAJB1
(blue). The monomeric molar ratio between chaperone and polyQ was
1:0.1. Molar ratios were calculated as monomer to monomer, although
DNAJB6 is oligomeric
Fig. 7 Suppression of
fibrillation by DNAJB6 with and
without HSPA1. Fibrillation was
measured as the relative ThT
fluorescence increase, and
incubation was made of 15 μM
Q45 (a, b) and HttEx1Q45 (c, d)
with no chaperone in the absence
(black) or presence (gray) of
HSPA1, with DNAJB6 in the
absence (red) or presence (pink)
of HSPA1, and with DNAJB1 in
the absence (dark blue) or
presence (light blue) of HSPA1.
The monomeric molar ratio
between chaperone and polyQ
was 1:0.01. Molar ratios were
calculated as monomer to
monomer, although DNAJB6 is
oligomeric
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Fibrillation suppression by DNAJB6 compared to other
DNAJB proteins To evaluate how specific the polyQ fibrilla-
tion suppression by DNAJB6 is compared to other DNAJB
proteins, we added DNAJB6, its close homologue DNAJB8,
and the more canonical family member, the structurally char-
acterized homologue DNAJB1. DNAJB6 suppressed fibrilla-
tion of Q45 entirely, DNAJB8 delayed fibrillation by a factor
of 4, and DNAJB1 delayed fibrillation only slightly, at a molar
ratio 1:0.1 (Fig. 6a). At a molar ratio 1:0.01 where DNAJB1
had no effect at all, DNAJB6 still delayed fibrillation with
nearly a factor 3 (data not shown). For HttExQ45, the fibrilla-
tion was delayed 2.5-fold with DNAJB6 and, to a small extent,
by DNAJB1 and DNAJB8 (Fig. 6b). The suppression of
polyQ fibrillation by DNAJB6 was not further enhanced in
presence of HSPA1 andATP (Fig. 7), confirming the finding in
cellular systems that suppression of polyQ aggregation by
DNAJB6 is HSPA1/ATP independent (Hageman et al. 2010;
Gillis et al. 2013). Thus, DNAJB6 has unique fibrillation
suppression properties, which are lacking in DNAJB1 and,
probably, are located in the C-terminal and putatively
substrate-binding domain which is not very conserved among
the many different DNAJB proteins. The sequence similarity
between DNAJB6 and DNAJB1 is largest in the N-terminal J
domain (59% sequence identity) and in the C-terminal domain
that has been structurally characterized for DNAJB1, showing
two β-sandwich folds each with 2+3 antiparallel β-strands
and one α-helix and α-helical dimerization domain (Suzuki
et al. 2010; Hu et al. 2008), and the sequence identity is too low
(17 %) for homology modeling. However, secondary structure
predictions and sequence alignment (Fig. S3), with the struc-
ture determined for DNAJB1 correlating well with the predic-
tion for DNAJB1, suggest that DNAJB6 and DNAJB8 have
one β-sandwich fold in the C-terminal domain (Fig. 8).
Discussion
Here, we have shown that the purified DNAJB6 protein
forms heterogeneous oligomers that cannot be separated into
more homogeneous fractions (Fig. 1, Table 1). This resem-
bles the polydisperse and dynamic oligomerization of some
small heat shock proteins for example αB-crystallin
(Baldwin et al. 2011). DNAJB6 efficiently suppressed fibril-
lation of Q45 and, less efficiently, suppressed fibrillation of
HttEx1Q45 (Figs. 3, 4, and 5). Furthermore, DNAJB6 was
undoubtedly more efficient in suppressing fibrillation than
DNAJB1 and independent on the presence of HSPA1 and
ATP (Figs. 6 and 8). These data obtained with purified
proteins provide evidence in support of the effects previously
observed in cells, when overexpression of DNAJB6 was
combined with expression of GFP-labeled huntingtin exon
1 (Hageman et al. 2010) and polyQ peptides (Gillis et al.
2013).
DNAJB6 was identified, together with its closest homo-
logue DNAJB8, as unique polyQ aggregation suppressors
among the human HSPA, HSPH, and DNAJ family members
(Hageman et al. 2010). The suppression was largely indepen-
dent of the expression of Hsp70 members. The absence of a
comparable polyQ aggregation inhibitory effect of DNAJB1
that shares a homologous J domain but has little sequence
resemblance with DNAJB6 in its C-terminus (only 17 %)
supports the crucial role for the C-terminal domain of
DNAJB6 and DNAJB8 in the polyQ aggregation suppression.
The DNAJB1 C-terminus lacks a serine-rich motif (SSF-SST)
and two lysines that were found to be important for the anti-
aggregation function (Hageman et al. 2010) (Fig. 8).
DNAJB6 was more efficient in suppressing fibrillation of
polyQ peptides than HttEx1 with polyQ stretches of identical
Fig. 8 Secondary structure prediction to assess the C-terminal domain
of DNAJB6. Secondary structure prediction, with predicted α-helices
in red, predicted β-strands in yellow for human DNAJB6b (isoform B,
sp|O75190-2), its closest paralogue DNAJB8 (sp|Q8NHS0), and its
more distantly related paralogue, DNAJB1 (sp|P25685) for which the
structure has been determined to atomic resolution [PDB:1HDJ for the
N-terminal domain (Qian et al. 1996), PDB:3AGX for the C-terminal
domain (Suzuki et al. 2010)], with α-helices as red and β-strands as
yellow boxes below the aligned sequences
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length, as assessed by ThT fluorescence (Fig. 3) and the for-
mation of SDS-insoluble aggregates (Fig. 5). There may be
several reasons for this. The fibrillation-promoting properties of
the polyQ-flanking regions within HttEx1 might counteract
DNAJB6-mediated inhibition, or these regions might disfavor
the interaction between DNAJB6 and polyQ. The polyQ con-
text, specifically the 17 N-terminal amino acids in HttEx1,
significantly increases polyQ fibrillation propensity (Wetzel
2012); (Papaleo and Invernizzi 2011), which could make it
more difficult to counteract fibrillation. The inhibition of
polyQ aggregation by DNAJB6 anyway appears to be largely
context independent with the polyQ stretch as the only com-
mon denominator, since DNAJB6 was also very efficient at
suppressing aggregation of other polyQ-containing proteins,
like ataxin-3 and the androgen receptor (Hageman et al. 2010).
So, how can our current findings of highly efficient sup-
pression of polyQ peptide aggregation by DNAJB6 be related
to its anti-aggregation and toxicity-preventing effects in cel-
lular (Hageman et al. 2010; Chuang et al. 2002) and animal
models (Hageman et al. 2010; Fayazi et al. 2006) of polyQ
diseases? One obvious possibility relates to the findings that
proteins containing expanded polyQ stretches are not fully
degraded by the proteasome (Venkatraman et al. 2004). As a
consequence, polyQ peptides that have a high propensity to
aggregate into fibrillar assemblies (Wetzel 2012) are released
from the proteasome during the degradation of huntingtin
(Holmberg et al. 2004; Venkatraman et al. 2004) and other
polyQ proteins. That free polyQ peptides are not readily
detected in cells can be due to their immediate capture by
DNAJB6-like chaperones and subsequent degradation by
peptidases or autophagy (Menzies et al. 2010). If such pro-
cessing fails, polyQ peptides would, however, become
enriched and immediately seed aggregation into both
main and side chain hydrogen-bonded fibrillar structures
(Berryman et al. 2009; Streets et al. 2013). Other proteins
containing Q stretches or protease-generated fragments of the
polyQ proteins next will co-aggregate with such peptides and
contribute to the toxicity by either direct aggregated toxicity or
(secondary) loss of function of these sequestered proteins. The
rate and propensity of this will likely depend on the context
around the polyQ stretches in these fragments (Dehay and
Bertolotti 2006). If released in the cellular environment upon
cell death, aggregates can be transmitted to neighboring cells
and act as seeds promoting the aggregation of endogenous
polyQ-containing proteins (Ren et al. 2001), reminiscent of
the spreading seen for the prion PrP (Brundin et al. 2010). To
mimic proteasomal release of polyQ peptides in living cells,
overexpression of genetically engineered constructs of polyQ
peptides was therefore performed, showing that the polyQ
peptides induced the formation of aggregates in which
polyQ-containing proteins and other heat shock proteins
(HSPs) were detected, supporting the view that polyQ pep-
tides can act as seeds for aggregation (Raspe et al. 2009).
Moreover, using the same cell system, it was recently
shown that co-expression of these genetically engineered con-
structs of polyQ peptides with DNAJB6 suppressed aggrega-
tion (Gillis et al. 2013). Interestingly, in the few aggregates
that did form, DNAJB6 and DNAJB8 were found in the core
of the aggregates, whereas other chaperones (HSPA1) only
associated with the periphery of the aggregates. This is indi-
cating that DNAJB6 interacts early and directly with polyQ
peptides as shown in this study, and the other HSPs interact
later and more indirectly, presumably not until after the ag-
gregates have formed.
To summarize, the data presented in this study show that
DNAJB6 can directly bind to and highly efficiently suppress
polyQ peptide fibrillation initiated by soluble, pure polyQ
peptides. This is in line with recent cellular findings that
DNAJB6 is a very strong protector against protein toxicity
associated with polyQ aggregation diseases. The view of
DNAJB6 as a peptide-binding chaperone that can sweep up
polyQ peptides that are incompletely degraded by and re-
leased from the proteasome and suppress fibrillation initia-
tion makes DNAJB6 an interesting target for therapy against
such protein aggregation diseases.
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